(Beijing / Chengdu Comprehensive News) As the number of crown diseases infected by China's crown disease has increased, the demand for crown disease treatment drugs has risen sharply.

Many pharmaceutical companies in China are accelerating the development of coronary drugs.Among them, Chinese domestic crown disease treatment oral medication has been completed, and the third phase has been completed, and it is expected to be listed as soon as February 2023.

"Jiangsu Drug Supervision" WeChat public account released news that the Jiangsu Provincial Drug Administration will go all out to help the SIM0417 (Xian Nuoxin (TM)), which helps Jiangsu Pharmaceuticals Pharmaceutical Pharmaceuticals, will be approved as soon as possible.

The

Announcement shows that SIM0417 is a 3CL target crown disease jointly developed by the Pionee Pharmaceuticals and the Shanghai Academy of Sciences Shanghai Pharmaceutical Research Institute and Wuhan Virus Research Institute for oral medication.On December 16th, the third phase of the project had been clinically completed. All 1,208 patients were completed. The progress was first in China ’s domestic 3CL target drug. It is expected to be available as soon as February 2023.

According to the Huaxia Times, in addition to the pioneering pharmaceutical industry, many companies such as Ge Li Pharmaceutical and Junshi Biological have recently released the development of crown disease oral medication, all of which are accelerating the development of drug research and development.

At present, Chinese domestic crown disease oral medication, which is in the later period of research and development, includes the first voice pharmaceutical SIM0417, all beings pharmaceutical RAY1216, the Junshi biological VV116, the frontier FB2001 atomizer inhalation agent, etc. In addition, there are more than ten domestic productsCrown disease oral medicine is in the R & D stage.

Hospital funeral home overload operation is facing tremendous pressure

At the same time, as the epidemic spreads rapidly, hospitals and funeral home across China are operating overload, facing tremendous pressure.

According to Reuters, the Chengdu Huaxi Hospital in the evening of Tuesday (December 27), the inside and outside the emergency department and the fever clinic have been lined up.However, the hospital does not have a special drug inventory of coronary diseases, and can only provide drugs such as cough and other symptoms.

The report of the People's Daily Online also quoted Mei Xue, deputy director of the emergency department of Beijing Chaoyang Hospital, said that there were about 100 patients in the hospital in the hospital every day, and now it has increased to 450 to 550. Among themPatients with critical illness are the main diseases, and the condition is more serious.

There are full queues in the funeral home in many places.At the Dongjiao's funeral home in Chengdu, the fire burial farm was full of smoke, and the funeral team continued. A staff member said that now they are too busy to eat time every day. Many people die from crown diseases. PreviouslyNow it has risen to 200 daily.Another worker in the Nanking Funeral Farm in Chengdu also pointed out that the number of thermal burials has been full, and it has been ranked New Year's Day and New Year.